| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
SpringWorks Therapeutics, Inc.$46.99
0 (0%)
B 61Pipeline Score Fair Value Biotech · Commercial
Market Cap
3.54 B
EPS
-3.41
P/E Ratio
-
Value Trade
235.48 M
0 %
Week
0 %
1 Month
0 %
3 Month
0 %
6 Month
0 %
5 Year
91.8 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
5.01 M
52 Week Range
null-null
% held by Insiders
3.19 %
% held by Institutions
97.88 %
Enterprise Value
3.26 B
Total Shares
75.35 M
Short %
8.75 %
Float Shares
72.94 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-02-28 | Mirdametinib | PDUFA Date | PDUFA | Approved | – | – | – |
2025-02-28 | Mirdametinib | PDUFA Date | PDUFA | Approved | – | – | – |
2025-02-28 | Mirdametinib | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
B61
Pipeline Score $10.0B
Pipeline ValueFair Value
Valuation Signal4
Drugs Scored2.8x
rNPV / MCap Top 91%
Small Cap (rank 84 of 923)
Percentile RankSpringWorks Therapeutics, Inc. holds a solid B-grade pipeline (61/100), with $16.7B risk-adjusted pipeline value, led by Nirogacestat in Tumor (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nirogacestat Small molecule | Desmoid Tumor | Phase 3 | NCT07170644 | 87% | $11.1B | ACTIVE NOT_RECRUITING | 190 | AVERAGE | D (27) | Oct 9, 2029 | - | LOW Jun 29, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
OGSIVEO | desmoid tumors | Phase 3 | 2025-10-21 | 34.3% (n = 24) in year 1; 45.7% (n = 32) in patients who received OGSIVEO for up to 4 years; 24 (34.3%) PRs and 8 (11.4%) CRs in total; −32.3% at year one (n=46); −75.8% (n=15) for patients completing at least four years of treatment Read More | SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology Read More | |
OGSIVEO | desmoid tumors | Phase 3 | 2025-10-21 | 34.3% (n = 24) in year 1; 45.7% (n = 32) in patients who received OGSIVEO for up to 4 years; 24 (34.3%) PRs and 8 (11.4%) CRs in total; −32.3% at year one (n=46); −75.8% (n=15) for patients completing at least four years of treatment Read More | SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology Read More | |
OGSIVEO | desmoid tumors | Phase 3 | 2025-10-21 | 34.3% (n = 24) in year 1; 45.7% (n = 32) in patients who received OGSIVEO for up to 4 years; 24 (34.3%) PRs and 8 (11.4%) CRs in total; −32.3% at year one (n=46); −75.8% (n=15) for patients completing at least four years of treatment Read More | SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SWTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SWTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How SWTX ranks across every disease it competes inCompetitive Position is a premium feature
See how SWTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial